The medication is generally used to address symptoms related to inflammatory or irritative states and underlying causes of mixed vaginal infections in adult women, and may be part of symptomatic management in conditions involving multiple pathogens and requiring local support. For combination ovules in this class, the product is primarily indicated for candidal, bacterial, trichomonal, and mixed vaginal infections.

---

Relief for Acute Discomfort and Inflammation

Sufrexal Combi is applied to ease symptoms related to these conditions, helping manage clustered symptoms such as intense itching (pruritus), burning, and abnormal vaginal discharge that create noticeable interference with daily comfort. The combination is considered relevant for easing symptoms that create noticeable physiological strain, assisting with maintaining functional stability and contributing to improved comfort. This therapy is commonly used in conditions presenting with acute episodes of vulvovaginal discomfort.

---

Quick Fact: Relief for Vulvovaginal Discomfort

This treatment is commonly used to help manage the intense itching and burning associated with active infection, helping to ease the overall symptom load and support general well-being during symptomatic phases.

---

Supporting Local Tissue Healing

The medication is relevant in clinical settings where the infectious process has led to mucosal damage or irritation. It may assist with supporting the healing of the vaginal lining, a process considered relevant when conditions produce significant symptomatic burden.

Regulatory References

1. Official FDA Philippines Product Information

Who can and cannot use Sufrexal Combi?

Eligibility to use Sufrexal Combi is officially determined by the absence of specific health conditions, physiological states, and documented allergies. The following categories reflect the essential constraints found in official regulatory labeling (e.g., FDA, EMA):

Populations Who Must Not Use (Contraindicated)

Classification	Basis for Exclusion (Official)
Hypersensitivity	Individuals with a known allergy or hypersensitivity to the active substance(s) or any component (excipients) of the Sufrexal Combi formulation.
Specific Conditions	Patients with any pre-existing medical condition that is explicitly listed as a formal contraindication in the official prescribing information for the active ingredients.

Restricted and Special Populations

Classification	Official Regulatory Status (Example)
Age Restriction	Use in pediatric populations (e.g., below 18 years of age) is typically not established or not recommended, meaning use is restricted unless specifically approved and labeled.
Physiological Status	Use during pregnancy and lactation is often classified as contraindicated or not recommended based on an official risk assessment, thus excluding these patient groups.
Organ Impairment	Individuals with severe hepatic or renal impairment may be restricted or excluded if the drug's metabolism or safety profile is compromised by the condition, as designated in the official label.

Official regulatory documents define ineligibility by listing these formal exclusions and restrictions, establishing that the drug is only appropriate for use in individuals who do not possess any of these officially documented exclusionary criteria.

Interactions with other medicines and products

Officially documented interaction patterns for Sufrexal Combi primarily relate to the systemic exposure risks of its components, Metronidazole and Miconazole. The regulatory profile is structured around mandated restrictions and classifications of interaction severity.

Formal Contraindications and Restrictions

The Metronidazole component is formally contraindicated with Disulfiram (taken concurrently or within two weeks) due to the risk of psychotic reactions. Consumption of Alcohol (Ethanol) is also contraindicated during and for a documented period following treatment (24 hours to three days) due to the risk of a disulfiram-like reaction. Furthermore, the ovule base may chemically interact with the material of latex-based contraceptive products (condoms and diaphragms), which carries a documented risk of product failure.

Exposure and Potentiation Risks

• Oral Anticoagulants: Co-administration with Coumarin derivatives (e.g., Warfarin) is documented to potentiate the anticoagulant effect, resulting in a prolonged prothrombin time. This risk stems from both Metronidazole and the Miconazole component's inhibition of the CYP3A4 enzyme system. This CYP inhibition also restricts the use of highly sensitive substrates, such as certain Statins and Ergot Alkaloids.
• Clearance Modifiers: Agents like Cimetidine may decrease the plasma clearance of Metronidazole, which increases systemic exposure. Concomitant use with Lithium has also been associated with documented elevated plasma concentrations of Lithium.
• Population Note: In patients with severe hepatic disease, the potential for accumulation of Metronidazole and its metabolites may increase systemic exposure and heighten the risk of interactions.

How Sufrexal Combi Works (Mechanism of Action)

Sufrexal Combi operates via a dual mechanism targeting the skeletal remodeling unit.

---

Targeting Osteoclast Resorption (Component A)

Component A, a calcitonin receptor agonist, initiates its effect by binding to the specific calcitonin receptor expressed on the osteoclast surface. This interaction triggers an intracellular signaling cascade, notably the activation of adenylyl cyclase. This cascade mediates the rapid inhibition of osteoclast mobility and concurrently reduces the intrinsic resorptive function of the cell, directly limiting bone breakdown.

---

Modulation of Bone Cell Turnover (Component B)

Component B, a vitamin D receptor activator, modulates the transcription of genes critical for mineral homeostasis. It acts by binding to the nuclear vitamin D receptor (VDR), influencing the expression of factors essential for bone mineralization and cellular turnover. The combined effect of Component A's direct inhibition and Component B's regulatory influence on bone cell differentiation results in an altered ratio of osteoblast-mediated bone formation to osteoclast-mediated bone resorption, thereby modulating the overall balance of bone remodeling.

The official administration instructions for Sufrexal Combi, typically formulated as a vaginal ovule or suppository combined with a cream, are defined by its specific dosage regimen to ensure proper local delivery of the active ingredients. Since this product is generally a combination gynecological treatment, its proper use is highly procedural and time-dependent.

Official Dosing and Route of Administration

Administration Scope	Official Labeled Instruction
Route of Administration	Vaginal. The ovule is for deep insertion; the cream is for topical external application (where supplied).
Dosing Schedule	One (1) unit (ovule/suppository) per day (once daily).
Timing and Frequency	Administer once daily, preferably at bedtime, to maximize local retention and absorption while minimizing leakage.
Course Duration	The full treatment course, typically 7 consecutive days, must be completed, even if symptoms improve.

Administration Procedure

Before use, hands must be washed thoroughly. The ovule should be removed from its wrapper and inserted as deep as possible into the vagina, usually while the patient is lying on their back with knees slightly drawn up.

Missed Dose Rule: If a dose is missed, it should be administered as soon as possible, unless it is close to the next scheduled dose, in which case the missed dose is skipped, and the regular schedule is resumed. No double dose should be taken.

Research Evidence / Overview of Studies for Sufrexal Combi

Evidence for use in Mixed Vaginal Infections

The research for the core antimicrobial components, Metronidazole and Miconazole, was evaluated in Randomized Controlled Trials (RCTs) and systematic reviews. The studies monitored outcomes related to physical discomfort, tracking the resolution of signs like discharge, itching, and burning in adult women with mixed infections (e.g., Bacterial Vaginosis, Candidiasis, or Trichomoniasis). Researchers examined both the Clinical Cure Rate (symptom resolution) and the Microbiological Cure Rate (pathogen clearance). While these findings describe patterns observed in the studies, comparative evidence is lacking regarding the full three-component combination against all alternative therapies.

Studies Evaluating Tissue Healing and Trophic Support

The Ketanserin component was studied for its potential association with tissue recovery, a question relevant in research contexts involving fluctuating or unstable symptoms. This evidence stems primarily from specialized mechanistic studies and trials focusing on re-epithelialization in general tissue damage models. In the context of vaginitis trials, the findings related to the trophic support component appear to be less systematically tracked as a primary outcome compared to antimicrobial clearance.

Long-Term Evidence and Durability of Effect

Studies conducted during periods of increased symptom activity were evaluated in trials assessing short-term or episodic symptom patterns. While initial follow-up durations were often limited (e.g., two weeks), some trials on the dual-component formulation monitored recurrence rates over defined time intervals, sometimes extending up to 12 months. Despite this extended data, the long-term effects are not fully established regarding the consistency of patterns observed over time.

Evidence in Specific Patient Groups and Research Gaps

Clinical research primarily focused on adult women aged 18 to 45, meaning the results apply only to the populations studied. Data for certain groups remain insufficient, as children and adolescents and pregnant or breastfeeding women were typically excluded from the main trials. Furthermore, there is limited information for long-term outcomes and a lack of comparative data isolating the specific contribution of the Ketanserin component to the overall cure rate.

Key Studies & References

1. Treatment and prevention of trichomoniasis, bacterial vaginosis and candidiasis with a new 7-day regime containing metronidazole and miconazole in a single vaginal pessary
2. COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Evidence-based classification

Common questions about Sufrexal Combi (FAQ)

Q: What is Sufrexal Combi used for?

Sufrexal Combi is used to treat vaginal thrush (candidiasis), a common fungal infection of the vagina. It contains two medicines: one is an antifungal medicine, and the other is a medicine that helps relieve the associated symptoms like itching and soreness.

---

Q: How do I use Sufrexal Combi?

Sufrexal Combi is typically applied once nightly for three nights in a row. The pack contains ovules (vaginal pessaries) and cream. You should insert the ovule high into the vagina at bedtime on three consecutive nights. The cream is for external use on the surrounding area (vulva) to relieve irritation and itching. Always follow the exact instructions provided in the patient information leaflet.

---

Q: What should I do if I miss a dose?

If you forget to use an ovule at bedtime, insert it as soon as you remember. If it is close to the time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not use a double dose to make up for a forgotten ovule. You must still complete the full course of three nights to ensure the infection is fully treated.

---

Q: What are the common side effects of Sufrexal Combi?

The most common side effects are mild and usually occur at the start of treatment. They include:

• A mild burning or stinging sensation immediately after inserting the ovule or applying the cream.
• Itching or redness in the treated area.

These symptoms are often temporary. If the irritation is severe, lasts longer than a few days, or if you develop new or worsening symptoms, stop using the product and consult a healthcare professional.

---

Q: Can I have sexual intercourse while using Sufrexal Combi?

It is generally recommended to avoid sexual intercourse while using this treatment and until the infection has cleared. The active ingredients in the ovules and cream may also damage latex contraceptives (condoms and diaphragms), making them ineffective at preventing pregnancy or sexually transmitted infections (STIs).

---

Q: What is the active ingredient in Sufrexal Combi?

Sufrexal Combi contains a combination of two active ingredients:

1. Miconazole nitrate (in the ovule and cream), which is an antifungal agent that treats the yeast infection.
2. Fluocinolone acetonide (in the cream only), which is a corticosteroid that helps reduce inflammation, itching, and redness.

How to Store and Dispose of Sufrexal Combi?

The official storage conditions for Sufrexal Combi ovules are established to protect the medication's integrity and stability. The product must be stored at a temperature not exceeding 30 C and must be kept in a dry place.

Storage Requirement	Condition
Temperature Constraint	Store below 30 C. Do not freeze.
Environmental Protection	Protect from light and moisture.
Packaging Rule	Keep in the original package until use.

It is a mandatory requirement to store the medicine out of the sight and reach of children.

For disposal, do not throw unused or expired ovules into wastewater or household trash. Patients must consult a healthcare professional, such as a pharmacist, for guidance on how to properly discard any medicine no longer needed, ensuring compliance with local pharmaceutical waste regulations.